Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: A multicenter, randomized, open-label study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 9, 2013, Pages 738-745

  Shen, Yang ^a   Huang, Xiao Jun ^b   Wang, Jian Xiang ^c   Jin, Jie ^d   Hu, Jian Da ^e   Yu, Kang ^f   Wu, De Pei ^g   Wang, Shu Jie ^h   Yu, Li ⁱ   Chen, Xie Qun ^j   Liu, Ting ^k   Liang, Ying Ming ^l   Chen, Fang Ping ^m   Li, Yan ⁿ   Shen, Zhi Xiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e FUJIAN MEDICAL UNIVERSITY   (China)

^f WENZHOU MEDICAL UNIVERSITY   (China)

^g THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^h PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

ⁱ CHINESE PLA GENERAL HOSPITAL   (China)

^j FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^k SICHUAN UNIVERSITY   (China)

^l FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^m CENTRAL SOUTH UNIVERSITY   (China)

ⁿ CHINA MEDICAL UNIVERSITY   (China)

more..

Author keywords

Invasive fungal infection; Posaconazole; Prophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; FLUCONAZOLE; POSACONAZOLE;

ABDOMINAL DISCOMFORT; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHINA; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HIGH RISK PATIENT; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NUTRITIONAL DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SKIN DISEASE; SOFT TISSUE DISEASE; SYSTEMIC MYCOSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 84885036892     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201880     Document Type: Article

References (27)

1. Denning DW. Early diagnosis of invasive asper-gillosis. Lancet. 2000; 355: 423-424.
2. Viscoli C, Girmenia C, Marinus A., Collette L, Martino P, Vandercam B., Doyen C, Lebeau B, Spence D., Krcmery V, De Pauw B, Meunier F. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999; 28: 1071-1079. (Pubitemid 29203541)
3. Cornely OA, Marty FM, Stucker F, Pappas P.G., Ullmann AJ Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease. Mycoses. 2011; 54: e838-e847.
4. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther. 2004; 2: 485-497. (Pubitemid 39162360)
5. Herbrecht R, Denning D W, Patterson T F, Bennett JE, Greene R.E., Oestmann J W, Kern W V, Marr KA, Ribaud P, Lortholary O., Sylvester R, Rubin RH, Wingard J.R., Stark P., Durand C, Caillot D, Thiel E., Chandrasekar PH, Hodges MR, Schlamm HT et al.; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole vs. amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408-415. (Pubitemid 34851833)
6. Walsh TJ, Teppler H, Donowitz G.R., Maertens JA, Baden LR, Dmoszynska A, Cornely O.A., Bourque MR, Lupinacci RJ, Sable CA, dePauw BE Caspofungin vs. liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004; 351: 1391-1402.
7. Hahn-Ast C., Glasmacher A, Mückter S, Schmitz A., Kraemer A, Marklein G, Brossart P., von Lilienfeld-Toal M. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosup-pressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother. 2010; 65: 761-768.
8. Kontoyiannis D.P., Marr KA, Park B.J., Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes D.R., Baddley J W, Brown JM, Brumble L.M., Freifeld AG, Hadley S, Herwaldt LA, Kauffman C.A., Knapp K., Lyon GM, Morrison VA, Papanicolaou G, Patterson TF et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50: 1091-1100.
9. Pagano L, Caira M, Candoni A., Offidani M, Martino B, Specchia G., Pastore D, Stanzani M, Cattaneo C., Fanci R, Caramatti C, Rossini F., Luppi M, Potenza L, Ferrara F., Mitra ME, Fadda RM, Invernizzi R, Aloisi T., Picardi M et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010; 95: 644-650.
10. Guiot H.F., Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant he-matologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis. 1994; 18: 525-532. (Pubitemid 24106902)
11. Kaskel P, Tuschy S, Wagner A., Bannert C, Cornely OA, Glasmacher A, Lipp H P, Ullmann AJ Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol. 2008; 87: 311-319. (Pubitemid 351445291)
12. Leather HL, Wingard JR Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom? Curr Opin Infect Dis. 2002; 15: 369-375. (Pubitemid 34816424)
13. Moen MD, Lyseng-Williamson KA, Scott LJ Li-posomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009; 69: 361-392.
14. Zaragoza R, Pemán J, Salavert M., Viudes A, Solé A, Jarque I, Monte E, Romá E, Cantón E. Multi-disciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther Clin Risk Manag. 2008; 4: 1261-1280.
15. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood. 2003; 101: 3365-3372. (Pubitemid 36857916)
16. Slavin MA, Osborne B, Adams R., Levenstein MJ, Schoch HG, Feldman AR, Meyers J.D., Bowden RA Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplan-tation - A prospective, randomized, double-blind study. J Infect Dis. 1995; 171: 1545-1552.
17. Vardakas KZ, Michalopoulos A, Falagas ME Fluconazole vs. itraconazole for antifungal prophylaxis in neutropenic patients with haemato-logical malignancies: a meta-analysis of ran-domised-controlled trials. Br J Haematol. 2005; 131: 22-28. (Pubitemid 43899704)
18. Sabatelli F, Patel R, Mann P A, Mendrick CA, Norris C.C., Hare R., Loebenberg D, Black TA, McNicholas PM. In vitro activities of posaconazole, fluco-nazole, itraconazole, voriconazole, and ampho-tericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006; 50: 2009-2015. (Pubitemid 43807519)
19. Cornely OA, Maertens J, Winston D.J., Perfect J., Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J., Stockelberg D, Goh Y T, Petrini M, Hardalo C., Suresh R, Angulo-Gonzalez D. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356: 348-359. (Pubitemid 46148777)
20. Farowski F, Vehreschild JJ, Cornely OA Posacon-azole: a next-generation triazole antifungal. Future Microbiol. 2007; 2: 231-243.
21. Cuenca-Estrella M., Gomez-Lopez A, Mellado E., Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006; 50: 917-921. (Pubitemid 43327795)
22. De Pauw B., Walsh TJ, Donnelly J P, Stevens DA, Edwards J.E., Calandra T., Pappas PG, Maertens J, Lortholary O, Kauffman C.A., Denning D W, Patterson T F, Maschmeyer G, Bille J., Dismukes WE, Herbrecht R, Hope W W, Kibbler CC, Kullberg BJ, Marr KA et al.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46: 1813-1821.
23. Segal BH, Herbrecht R, Stevens D.A., Ostrosky-Zeichner L, Sobel J, Viscoli C., Walsh TJ, Maertens J, Patterson T F, Perfect JR, Dupont B, Wingard J.R., Calandra T., Kauffman CA, Graybill JR, Baden LR, Pappas P.G., Bennett JE, Kontoyiannis D P, Cordonnier C et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008; 47: 674-683.
24. Trotti A, Byhardt R, Stetz J., Gwede C, Corn B, Fu K., Gunderson L, McCormick B, Morrisintegral M., Rich T, Shipley W, Curran W. Common toxic-ity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47: 13-47. (Pubitemid 30179675)
25. Miettinen OS. Survival analysis: up from Kaplan-Meier-Greenwood. Eur J Epidemiol. 2008; 23: 585-592.
26. Perea S, Patterson TF Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect. 2002; 17: 99-105. (Pubitemid 34680151)
27. Rotstein C, Bow EJ, Laverdiere M, Ioannou S., Carr D, Moghaddam N; The Canadian Fluconazole Prophylaxis Study Group. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis. 1999; 28: 331-340.